Athira Pharma, Inc. (ATHA)
After hours:
| Previous Close | 2.1800 |
| Open | 2.1700 |
| Bid | 2.1100 x 100 |
| Ask | 2.1500 x 200 |
| Day's Range | 2.1100 - 2.2200 |
| 52 Week Range | 1.3300 - 4.2980 |
| Volume | |
| Avg. Volume | 352,722 |
| Market Cap | 82.019M |
| Beta (5Y Monthly) | 2.78 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Sidoti Events, LLC's Virtual May Micro-Cap Conference
NEW YORK, NY / ACCESSWIRE / May 7, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day May Micro-Cap Conference taking place Wednesday and Thursday, May 8-9, 2024. The ...
- GlobeNewswire
Athira Pharma to Participate in Upcoming May Conferences
BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in May. Sidoti May 2024 Virtual Investor ConferenceFormat: Company PresentationDate and Time: Wednesday, May 8, 2024, from 10:45 a.m. - 11:15 a.m. ET Location: Virtual Th
- GlobeNewswire
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
Experienced clinical development leader with a strong track record of advancing therapeutics from early development to approval and commercializationBOTHELL, Wash., April 15, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Javier San Martin, M.D., as Chief Medical Officer. Dr. San Martin brings more than 25 ye
